Introduction
Accumulating evidence suggests that brain-adipose tissue bidirectional communications might be promising intervention point for cardiometabolic and neurodegenerative diseases (1). Alzheimer's disease (AD) is a progressive and yet incurable disorder characterized by memory loss and cognitive ability deterioration. It is the most common form of dementia, a icting millions of humans globally. Although the progression of AD currently cannot be stopped or reversed, an increased understanding of its pathogenesis may give patients and their families chance for new therapies, which may at least delay the progress of the disease.
Although the human brain is nearly 50 percent lipids, the brain is the only organ which does not contain adipose tissue, except that located at the parasellar region, traditionally known as the cavernous sinus (Weninger WJ Today, we know that essential fatty acids, particularly the omega-3 fatty acids and decosahexaenoic acid (DHA), play important role for brain development and are among the most crucial molecules that determine a large spectrum of brain's functions (for brain GPR40, a receptor for free fatty acids, see Tonchev et al in the section "Abstracts from 4
th ISAA" published in this volume of Adipobiology).
To maintain metabolic and anthropometric homeostasis, the brain must precisely monitor the peripheral energy state. is monitoring is also extremely important for the brain's survival, because the brain does not store energy but depends solely on a continuous supply of nutrients from the blood circulation.
Brain-adipose misunderstanding may lead to various metabolic diseases including obesity, type 2 diabetes mellitus, metabolic syndrome and AD. Here we Dance Round the hypothesis of brain diabetes and adipose AD, white adipose tissue (WAT) being in the scope of the hypothesis.
Neuroadipocrinology
Both phenotypes of human life, the health and the disease, require the interaction between the cells of nervous system and the cells of other systems. One of the biggest recent achievements of neurobiology and adipobiology is the study on neurotrophic factors, e.g. nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) (2-4), insulin-like growth factor-1 (5), and adipokines, e.g. leptin, adiponectin, resistin and apelin (6-10; 11 for adipose-derived NGF and BDNF).
As o en occurs, the framework of an initial concept of the role of newly discovered molecules extends in the light of emerging ndings. is was also the case with neurotrophic factors and adipokines. For instance, for some 30 years a er the discovery of NGF, there have been few hints to indicate that it may act
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Adipose Alzheimer 38 DANCE ROUND on non-neuronal cells. us, it was remarkable when Aloe and Levi-Montalcini have discovered in 1977 that the treatment of newborn rats with NGF caused a systemic increase in the number of mast cells. is seminal nding paved the road of a novel research eld, the neuroimmunology (12). In the same context, the adipose tissue is no more considered mostly a lipid storage but a dynamic endocrine and paracrine organ producing a dazzling number of signaling proteins collectively termed adipokines (6) . Currently, their number estimated to be over 600 (7) . Some of them mediate the cross-talk between adipose tissue and brain in regulating food intake and energy homeostasis. However, the brain (mostly hypothalamus) is not the only target for leptin and other adipokines, as well as the food intake is not the only biological e ect of these adipokines. Rather, some adipokines support various metabolic and cognitive functions and exert both metabo-and neurotrophic actions (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Current data of adipose-derived neuroendocrine and neurotrophic factors are summarized in Tables 1, 2 . is raises an intriguing question as to whether adipose tissue might be a peripheral counterpart of hypothalamus-hypophysis, a part of di use neuroendocrine system, or our third brain (Obesity 
From brain diabetes to adipose Alzheimer's disease
Epidemiological evidence supports the observation that subjects with type 2 diabetes mellitus are at higher risk to develop AD. An estimated 312 million people su er from type 2 diabetes while AD a ects nearly 45 million people worldwide. Whether and how these two diseases are causally linked is not yet known.
Adipose tissue and brain of high fat diet fed animals expressed increased levels of proin ammatory cytokines and macrophage activation. Noteworthy, both brain and adipose tissue also have elevated amyloid precursor protein (APP) levels. Indeed, obesity, diabetes and/or metabolic syndrome may a ect multiple cognitive functions including expression of APP, amyloid-β (Aβ) peptide and tau hyperphosphorylation -molecular signatures of AD pathology. In brief, an extraneuronal production of both APP and Aβ peptides including the adipose tissue was demonstrated (25) (26) (27) (28) (29) (30) . Accordingly, the administration of streptozotocin (STZ), a well known experimental model for diabetes, induces brain insulin resistance and cognitive alterations resembling those in AD patients (31) (32) (33) . We have reported that STZ-induced diabetes is associated with changes in NGF levels in both pancreas and brain (34) . In e ect, STZ treatment became a new experimental tool in studying AD, which is increasingly evaluated as type 3 diabetes (33, 35) . To focus on the Table 2 . Metabotrophic e ects of NGF, BDNF and adiponectin (APN) NGF shares homology with proinsulin NGF and BDNF are produced by pancreatic beta cells and exert insulinotropic e ect NGF and BDNF are trophic factors for pancreatic beta cells APN is anti-obesity, anti-diabetogenic, anti-atherogenic adipokine BDNF-and APN -de cient mice develop abnormalities similar to the metabolic syndrome BDNF and APN improve cognitive processes NGF up-regulates expression of LDL receptor-related protein NGF up-regulates expression of PPAR-gamma NGF inhibits glucose-induced down-regulation of caveolin-1 NGF improves skin and corneal wound healing NGF and APN improve vascular (atheroma) wound healing NGF rescues silent myocardial ischemia in diabetes mellitus NGF improves diabetic erectile dysfunction Healthy lifestyle increases brain and/or circulating levels of NGF, BDNF, APN Atherogenic diet decreases brain BDNF levels brain-metabolism link (36-55) the concept of cognitive diabetes and brain diabetes was recently introduced (56, 57; for the antidiabetic drug metformin and APP processing, see 58, 59) . Again, many studies demonstrated that the adipokine leptin has a "therapeutic" e ect on the APP processing and tau phosphorylation (16-24).
As mentioned above, AD is characterized by the accumulation of Aβ and hyperphosphorylated tau, a microtubule-associated protein. e deposit of Aβ is a result of an imbalance between Aβ production and clearance. Among several proteases involved in the proteolysis of Aβ, neprilysin (neutral endopeptidase, NEP), a type II membrane-associated metalloendopeptidase, appears to be the most important Aβ-degrading enzyme in the brain, thus exploration of possibilities for NEP delivery is required. Accordingly, it was reported that human adipose tissue-derived stem cells (ADSC) secrete exosomes carrying enzymatically active NEP. When ADSC-derived exosomes were transferred into cultured nerve cells a decrease both secreted and intracellular Aβ levels in the treated cells was found (60) , suggesting the therapeutic relevance of these extracellular signaling vesicles for AD.
Altogether, our hypothesis of adipose tissue as a third brain working in tandem with that located "within the head" (Greek, enkephalon), herein referred to as adipose AD, might sound more plausible at present.
Further, diabetes mellitus and AD are both common and increasing incidence in the aging population. Recent evidence has demonstrated common pathogenic factors operating in both conditions. Some proof-of-hypothesis of adipose AD may also derive from the results demonstrating that the circulating and/or tissue levels of NGF, BDNF and adiponectin are commonly decreased in both cardiometabolic and neuropsychiatric diseases, including AD (reviewed in 3, 4, 15) . us, adipobiology of the brain has emerged as a challenging area of biomedical research. Its relevance to brown adipose tissue (BAT) also requires research attention.
Conclusion
e present Dance Round suggests that understanding precisely the neuro-adipose interactions (61, 62) may provide new insights in the pathogenesis and the therapy of obesity, diabetes, metabolic syndrome and AD. Further studies may lead to or exclude the possibility that adipose tissue also "su ers" from AD, or at least extend our knowledge of viewing AD as a metabotrophin-de cient disorder, as previously proposed for obesity and related diseases (63, 64) .
In 1999 Albee Messing published in Hepatology (29: 602-603) an editorial entitled "Nestin in the liver -lessons from the brain. "
He wrote: "Most neuroscientists manage to get through each day without thinking of the liver even once… but I think that is about to change. " is may also be the case for adipose tissue.
Today, physicians must accordingly be aware of the increased risk of cognitive de cit in patients with cardiometabolic diseases. And vice versa, to look for alteration of glucose, lipid and adipokine metabolism in patients with AD. Moreover, recent genome wide association study (GWAS) ndings provide information for the design of future novel therapeutic approaches for a subpopulation of type 2 diabetic subjects with genetic disposition to AD, that could bene t diabetes and reduce the risk for subsequent development of AD dementia (55) .
Of note, a er Alois Alzheimer's clinical report of "presenile dementia" on 3 November 1906, the rst Italian contributions to the histopathological and clinical description of AD dementia was published by Gaetano Perusini in three papers between 1906 and 1911 (Lucci B. e contribution of Gaetano Perusini to the de nition of Alzheimer's disease. Ital J Neurol Sci 1998; 19: 49-52). To appreciate the contribution of Perusini, our hypothesis should be named adipose Alzheimer-Perusini's disease.
